VIA.F VIATRIS INC. O.N.
- Market cap
- EUR 21.6B
- P/E
- -
- P/B
- 1.72x
- ROE
- -2.6%
- Dividend yield
- 2.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is VIA.F undervalued?
Graham numberThe Graham number of VIATRIS INC. O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VIATRIS INC. O.N. fundamental analysis
No fundamental analysis for VIATRIS INC. O.N. yet.
VIATRIS INC. O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VIATRIS INC. O.N.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering variou…
Full company profileVIATRIS INC. O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VIATRIS INC. O.N. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 16.3B | 15.4B | 14.7B | 14.3B | 14.7B |
| Gross Profit | 6.50B | 6.44B | 5.62B | 5.01B | 5.40B |
| Operating Income | 1.66B | 1.56B | 710M | 254M | 412M |
| EBITDA | 6.43B | 3.52B | 2.82B | -395M | 2.95B |
| Net Income | 2.08B | 54.7M | -634M | -3.51B | -357M |
| EPS | 1.71 | 0.05 | -0.53 | -3.05 | -0.31 |
| Balance Sheet | |||||
| Total Assets | 50.0B | 47.7B | 41.5B | 37.2B | 34.7B |
| Total Liabilities | 28.9B | 27.2B | 22.9B | 22.5B | 21.0B |
| Shareholders' Equity | 21.1B | 20.5B | 18.6B | 14.7B | 13.7B |
| Cash & Short-term Investments | 1.26B | 992M | 735M | 1.32B | 1.79B |
| Cash Flow | |||||
| Operating Cash Flow | 3.00B | 2.90B | 2.30B | 2.32B | 2.23B |
| Capital Expenditure | 489M | 575M | 359M | 465M | 363M |
| Free Cash Flow | 2.51B | 2.33B | 1.94B | 1.85B | 1.86B |
| Ratios | |||||
| ROE | 9.9% | 0.3% | -3.4% | -23.9% | -2.6% |
| ROA | 4.2% | 0.1% | -1.5% | -9.5% | -1.0% |
| Net Profit Margin | 12.8% | 0.4% | -4.3% | -24.6% | -2.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VIATRIS INC. O.N. dividends
- Dividend yield
- 2.34%
- Forward dividend
- 0.43 EUR
- Payout ratio
- -
- Ex-dividend date
- Nov 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 561M | 0.49 | - |
| 2024 | USD 575M | 0.48 | - |
| 2023 | USD 576M | 0.48 | 1,052.3% |
| 2022 | USD 582M | 0.48 | 28.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns VIATRIS INC. O.N.
- Insiders 0.32%
- Institutions 96.32%
- Public & others 3.37%
- Shares outstanding 1.15B
- Free float 1.14B
VIATRIS INC. O.N. company profile
- Company name
- VIATRIS INC. O.N.
- Ticker
- VIA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 30,000
- Fiscal year end
- December
- Address
- Robert J. Coury Global Center, Canonsburg, PA, United States, 15317
- Phone
- 724 514 1800
- Website
- viatris.com
About VIATRIS INC. O.N.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VIATRIS INC. O.N. management
10- Mr. Scott Andrew Smith Ph.D.CEO & Director · born 1962
- Mr. Andrew EnriettiChief Administrative & Transformation Officer · born 1985
- Dr. Corinne M. Le Goff M.B.A., Pharm.D.Chief Commercial Officer · born 1965
- Mr. Paul B. CampbellInterim CFO, Chief Accounting Officer & Corporate Controller · born 1967
- Mr. Ramkumar V. RayapureddyChief Information Officer
- Mr. William Szablewski C.F.A.Head of Investor Relations & Capital Markets
- Mr. Matthew Joseph MalettaChief Legal Officer · born 1972
- Ms. Lara RamsburgChief People & Corporate Affairs Officer
- Mr. Philippe MartinChief R&D Officer · born 1976
- Mr. Peter McCormickChief Supply Officer